Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Exelixis Inc EXEL

Healthcare Biotechnology
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved... see more

Recent & Breaking News (NDAQ:EXEL)

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

Business Wire November 7, 2024

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Business Wire October 29, 2024

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Business Wire October 15, 2024

Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

Business Wire October 15, 2024

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma

Business Wire October 14, 2024

ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

Canada NewsWire October 9, 2024

Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

Business Wire September 16, 2024

Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024

Business Wire September 15, 2024

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September

Business Wire August 28, 2024

Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Business Wire August 6, 2024

Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors

Business Wire August 6, 2024

Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

Business Wire July 23, 2024

Exelixis to Present at the William Blair 44th Annual Growth Stock Conference

Business Wire May 28, 2024

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Business Wire May 20, 2024

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

Business Wire May 7, 2024

Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update

Business Wire April 30, 2024

Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024

Business Wire April 16, 2024

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March

Business Wire February 27, 2024

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

Business Wire February 6, 2024

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February

Business Wire February 1, 2024